How emerging biotechs can enter the Chinese market and prosper
Small and emerging biotechs in the United States and Europe have long been wary of trying to enter the Chinese market, despite its vast potential. They’ve shied away due to changing regulatory and reimbursement policies, unreliable intellectual property protections, and fear that the Chinese government may favor domestic firms. But things have changed, and companies don’t need to be hesitant anymore.
Since 2015, a slew of economic and regulatory reforms have improved the Chinese market dynamics for foreign companies. In 2018, the Chinese State Council eliminated tariffs (of 6% to 10%) on all imported cancer drugs and slashed the value-added tax on them from 17% to 3%. In 2020, 28 new drugs from nondomestic companies were approved by the National Medical Products Administration (NMPA), faster and more dependably than before. In May 2021, China was reelected for a three-year term to the management committee of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, further aligning it with international regulatory standards.
Large international pharma companies often include China because of its market size, and many put it near the top of the list when sequencing global marketing submissions. But how can small and emerging foreign companies with limited resources gain a foothold in the Chinese market? Here are five approaches that help.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026